It is excreted into breast milk in non-significant amount. Plasma level in infants from mother who receive Fluvoxamine is usually undetectable. Not effects on the infant's physical and psychomotor development at both short or long-term were found. Because there is less experience published than with other antidepressants of the same pharmacological group, it should be preferred the use of an alternative drug that is known to be safer in the neonatal period or prematurity. Galactorrhea has been observed but less frequently than with other antidepressants. In cases of treatment with xanthines (theophylline, caffeine) for apnea of prematurity, the plasma level of them should be monitored because Fluvoxamine is a strong inhibitor of activity of the Cytochrome P450-CYP1A2 which is responsible for metabolic elimination of xanthines. Women who use antidepressant medication during pregnancy are in need of more support for breastfeeding since they are at risk for early weaning.